XBiotech Inc.
XBITAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Piper Sandler | maintain | Overweight | Apr 7, 2020 |
| PiperJaffray | maintain | Overweight | Dec 11, 2019 |
| Piper Sandler | maintain | Overweight | Dec 11, 2019 |
| Piper Sandler | maintain | Overweight | Jun 14, 2019 |
| Piper Jaffray | maintain | Overweight | Jun 14, 2019 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.22 | $0.03 | — | $7.0M |
| May 14, 2026 | $-0.18 | $0.03 | — | $7.0M |
| Mar 13, 2026 | $-0.88 | $0.04 | — | $7.0M |
| Nov 12, 2025 | $-0.20 | — | — | — |
| Aug 13, 2025 | $-0.06 | — | — | — |
| May 14, 2025 | $-0.36 | — | — | — |
| Mar 18, 2025 | $-0.34 | — | — | — |
| Nov 13, 2024 | $-0.16 | — | — | — |
News
AUSTIN, Texas, Oct. 23, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced that its Board of Directors have elected Jan-Paul Simard to serve as Co-Chief Executive Officer alongside CEO Dr. Sushma Shivaswamy, effective Oct. 23, 2026.
Investigator-sponsored study funded by the French National Cancer Institute (INCa) meets pre-specified primary efficacy success criterion with 61.3% 12-month overall survival.
XBiotech Inc. (NASDAQ: XBIT - Get Free Report)'s stock price passed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $2.27 and traded as low as $2.17. XBiotech shares last traded at $2.17, with a volume of 21,881 shares trading hands. Analyst Ratings Changes Separately,